In this week’s newsletter: standardizing advanced therapy manufacturing, the benefits of biocatalysts, NASH drug development, and coated implants. We’d also like to make you aware of a change to the upcoming newsletter schedule. Right now, you are used to receiving your weekly dose of medicine making news on Thursdays, but from March 5 you will instead be receiving the newsletter on Fridays.  


Stephanie Sutton, Editor
 
DRUG DELIVERY
Painting the Future of Drug Delivery
02/19/2021 | James Strachan
US Army combat veteran Luis Alvarez has developed a new drug delivery technology that can convert recombinant proteins into material-binding variants.
DRUG DISCOVERY
Breaking a Therapeutic Curse
02/18/2021 | Grit Zahn
New approaches are underway for treating nonalcoholic steatohepatitis.
STANDARDS & REGULATION
How to Standardize Advanced Therapy Manufacture
02/20/2021 | James Strachan
Cell and gene therapy manufacturing technologies and methods are advancing rapidly, but can regulators keep up?
SMALL MOLECULES
Are You a Bio-Catalytic Converter?
02/09/2021 | Alice Dunbabin
Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.
 
Webinar
Smart Shipping Solutions For Cell Therapy Logistics

Our webinar with Cytiva on overcoming cell therapy logistics without the hazards of liquid nitrogen is now available to view on demand. Stream now
 
White Papers
Understanding Excipient Functionality in a Formulation

The aim of formulation development is to design a product and its manufacturing process to consistently deliver the intended Quality Target Product Profile (QTPP).  Read More.
Benefits of Using Nanoparticle Tracking Analysis in Nanoscale Material Characterization

The production of nanoscale materials includes use and experimentation with a wide range of substances. Read More.
 
Special Promotions
Help us measure “Pandemic Impact” in Biopharma for a chance to win $100!

Take the “Pandemic Impact: Biopharma Trends 2021 Survey” now and you could win a $100 Amazon voucher (or a charitable donation, if preferred). Start Survey
A dedicated cell + gene therapy newsletter from The Medicine Maker team

Join 1,000s of peers from across the pharmaceutical, investment, and regulatory sectors for expert insight, analysis and words of wisdom on everything cell + gene therapy. Subscribe Now
 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.
Find out more
This email was sent to {~email~} by info@themedicinemaker.com. To ensure delivery of emails to your inbox, please add info@themedicinemaker.com to your address book or safe sender list. To view online, please click here.

Create or manage your account here
Unsubscribe here

The Medicine Maker is a brand of Texere Publishing Limited

Texere Publishing Limited, Booths Park 1,
Chelford Road, Knutsford, WA16 8GS, UK
Registered Company Number: 08113419
Texere Publishing Inc., 115 Broadway, FL 5,
New York, NY 10006, USA
Federal Identification Number: 81-4613586